Bilcare Limited
Add to watch list to get report alerts
BSE Code:
526853
NSE Code:
BI
Business Profile
Business Profile
Bilcare (BI) is a provider of pharmaceutical research services, clinical services and packaging systems and material. It was incorporated as a private limited company on July 1, 1987 and converted into a public limited company on Oct. 27, 1994.
The ISO 9001:2000 certified company offers research services including pre-formulation studies, formulation development, analytical research, stability studies, packaging audit, packaging development and design, and customized packaging solutions; clinical services such as project management, product and protocol design, batch manufacturing, primary packaging, labeling & randomization, kit assembly, distribution, ivrs, returns management, and controlled substances management.
Creating innovative product differentiation through packaging and vast experience of working with over 500 pharma manufacturers worldwide, the company offers global expertise in packaging development and operations. It is an established supply chain partner meeting packaging needs of leading pharma manufacturers. The state-of-the-art manufacturing and R&D facilities are located in India, Singapore and USA. It has alliances with National Chemical Laboratory, Pune for specialized research; PRS Permacel for anti-counterfeit devices and systems, Sam-A, Korea, for innovative pharma packaging foil solutions; and Precision Gears, a subsidiary of IMA, S.p.A., Italy, for an interface in packaging complexities.
Bilcare Singapore, a wholly owned subsidiary, has Bilcare GmbH, Germany; Bilcare, USA; Bilcare Farmaceutica Embalagem E Pesquisas, Brazil; Bilcare UK); Bilcare Switzerland SA; and the recently acquired Singular ID. DHP is a wholly owned subsidiary of Bilcare (UK). The company has a worldwide presence in over 20 countries covering Asia (Singapore), Europe (Frankfurt), North America (New Jersey), South America (Brazil) and others. The client list includes Abbott, Ranbaxy, Dr. Reddy`s, Aurobindo Pharma, Lupin Laboratories, Sun Pharma, Ipca Laboratory and global majors like Aventis India, Pfizer India, Novartis India, Bayer India among others.
The registered office is located at 1028, Shiroli Village, Khed taluka, Rajgurunagar, Pune-410505, Maharashtra.
Financials
Bilcare registered a 16.83% growth in net profit to Rs 165.9 million for the quarter ended December 2007 from a profit of Rs 142 million for the quarter ended December 2006.
Net sales rose 24.74% to Rs 1,041.2 million for the quarter ended December 2007 from Rs 834.7 million for the quarter ended December 2006.
Total income rose 23.39% to Rs 1,074.4 million for the quarter ended December 2007 from Rs 870.7 million for the quarter ended December 2006.
The earnings per share (EPS) of the company stood at Rs 10.08 for the quarter ended December 2007.
Recent Developments
03-JAN-08
Bilcare announced that Bilcare Singapore has bought 100% of Singular ID, the provider of integrated high technology enterprise brand security system, for a consideration of Singapore Dollar 19.58 million. Bilcare Singapore is a wholly owned subsidiary of the company.
16-MAY-07
Bilcare Research on May 16, 2007 announced the launch of the Bilcare Research Academy in partnership with Association of Clinical Research Professionals (ACRP), US. The academy shall open up 25 centers in India and other parts of Asia by 2010 with an initial investment of Rs 200 million. This will be the first ever ACRP accredited professional educational course in the Asian region brought through an exclusive tie-up. ACRP will also establish its Indian chapter and launch its activities in the entire South East Asia
Future Plans
Bilcare plans more satellite research centers across the globe in various global pharmaceutical hubs. This will ensure that customers in every region of the world will have a more direct access to the technical team of Bilcare Research, leading to an enhanced speed and quality of services provided.
Bilcare`s Center of Excellence at Pune is also being expanded to cater to the significantly increasing needs of the global pharmaceutical sector.